NA
ADMA icon

Navellier & Associates’s ADMA Biologics ADMA Stock Holding History

Navellier & Associates’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,036
Closed -$176K – 329
2025
Q3 		$176K Sell
12,036
-157,924
-93% -$2.71M 0.02% 352
2025
Q2 		$3.09M Sell
169,960
-870
-0.5% -$17.7K 0.38% 71
2025
Q1 		$4.05M Sell
170,830
-7,915
-4% -$137K 0.56% 47
2024
Q4 		$3.07M Buy
+178,745
New +$3.36M 0.37% 70

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Navellier & Associates's ADMA Position: Q4 2025 in Review

Navellier & Associates sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 12,036 shares — an estimated $176K sold.

Navellier & Associates first reported a position in ADMA in Q4 2024 and held it in 4 quarters. The position peaked at $4.05M in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

  • Navellier & Associates reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
  • Navellier & Associates sold 12,036 ADMA Biologics shares in Q4 2025, an estimated $176K.
  • Navellier & Associates first reported a position in ADMA Biologics in Q4 2024 and held it in 4 quarters.
  • Navellier & Associates's ADMA Biologics position peaked at $4.05M in Q1 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on Navellier & Associates's 13F filing for Q4 2025, filed 3 Feb 2026.